J & J to Acquire Proteologix; Portfolio Includes Bispecific Antibodies Aimed at AD
Johnson & Johnson will acquire Proteologix, Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with potential for an additional milestone payment. Proteologix’s portfolio includes PX128, a bispecific antibody targeting IL-13 plus thymic stromal lymphopoietin (TSLP), which is ready to enter phase 1 development for moderate to severe atopic […]